Experimental Drug Cuts Childhood Epilepsy Seizures by 91% in Clinical Trial

A revolutionary gene therapy is offering unprecedented hope for children with Dravet syndrome, one of the most severe forms of childhood epilepsy. The experimental drug zorevunersen reduced seizures by up to 91% in clinical trials, representing a potential breakthrough for families facing this devastating genetic condition.

Dravet syndrome affects children with a faulty SCN1A gene, causing frequent seizures that resist conventional treatments. The condition also leads to developmental delays, feeding problems, movement difficulties, and increased risk of premature death. Current medications often fail to provide adequate seizure control and don't address the cognitive complications.

Zorevunersen takes a novel approach by targeting the genetic root cause. While people with Dravet syndrome have one defective copy of the SCN1A gene, they retain one healthy copy. The drug works by boosting protein production from this functional gene copy, helping restore more normal nerve cell signaling and reducing seizure activity.

The international trial, led by University College London and Great Ormond Street Hospital, followed 81 children for three years. Beyond dramatic seizure reduction, researchers observed improvements in thinking, behavior, and overall quality of life. Most side effects were mild and well-tolerated.

These promising results have prompted a larger Phase 3 trial to further validate the treatment's effectiveness. If successful, zorevunersen could become the first therapy to directly address both the seizures and cognitive challenges of Dravet syndrome, potentially transforming outcomes for affected children and their families.